Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 1/2020

Open Access 01-01-2020 | Meningioma | Review

Hormone Replacement Therapy in Cancer Survivors – Review of the Literature

Authors: Tamás Deli, Mónika Orosz, Attila Jakab

Published in: Pathology & Oncology Research | Issue 1/2020

Login to get access

Abstract

Rapid advance in oncology leads to increasing survival of oncologic patients. More and more of them live long enough to reach either the natural age of menopause or, as a side effect of their oncotherapy, experience the cessation of gonadal function, leading to premature ovarian insufficiency, with disturbing vasomotor symtoms and long-term negative cardiovascular and skeletal effects. Thus, an ever increasing number of cancer survivors search endocrinologic help in the form of hormone replacement therapy (HRT). The misinterpretation of the WHI (Women's Health Initiative) Study has lead to an irrational fear of female hormone replacement, both by the general population and medical professionals. It has seemed the logical and safe conclusion to many physicians to avoid HRT, supposing that this attitude definitely causes no harm, whereas the decision of prescribing estrogen alone or with progestins might bear oncologic and thromboembolic risks and may even lead to litigation in case of a potentially related complication. However, it was known even before the WHI results that premature menopause and hypogonadism decreases the life expectancy of women by years through its skeletal and cardiovascular effects, and this negative effect correlates with the length of the hypoestrogenaemic period. Therefore, the denial of HRT also needs to be supported by evidence and should be weighed againts the risks of HRT. Yet, the oncologic risk of HRT is extremely difficult to assess. In this work we review the latest evidence from in vitro experiments to clinical studies, regarding HRT in survivors of gynecologic and non-gynecologic cancers. Based on our literature research, we group tumours regarding the oncologic risk of properly chosen female hormone replacement therapy in cancer survivors as follows: ’HRT is advanageous’ (e.g. endometrial cancer type I, cervical adenocarcinoma, haematologic malignancies, local cutaneous malignant melanoma, colorectal cancer, hepatocellular cancer); ’HRT is neutral’ (e.g. BRCA 1/2 mutation carriers without cancer, endometrial cancer type II, uterinal carcinosarcoma and adenosarcoma, certain types of ovarian cancer, cervical, vaginal and vulvar squamous cell carcinoma, prolactinoma, kidney cancer, pancreatic cancer, thyroid cancer); ’HRT is relatively contraindicated’ for various reasons (e.g. leiomyosarcoma, certain types of ovarian tumours, brain tumours, advanced metastatic malignant melanoma, lung cancer, gastric cancer, bladder cancer); ’HRT is diasadvantageous and thus contraindicated’ (e.g. breast cancer, endometrial stroma sarcoma, meningioma, glioma, hormone receptor positive gastric and bladder cancer).
Literature
1.
Baber RJ, Panay N, Fenton A, Apr, IMS Writing Group (2016) IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric(2):109–150
2.
Lumsden MA, Davies M, Sarri G, Guideline Development Group for Menopause: Diagnosis and Management (NICE Clinical Guideline No. 23) (2016) Diagnosis and Management of Menopause: The National Institute of Health and Care Excellence (NICE) Guideline. JAMA Intern Med 176(8):1205–1206CrossRefPubMed
3.
ACOG Practice Bulletin No. 141: management of menopausal symptoms. (2014) Obstet Gynecol. 123(1):202-16.
4.
Ossewaarde ME, Bots ML, Verbeek AL, Peeters PH, van der Graaf Y, Grobbee DE, van der Schouw YT (2005) Age at menopause, cause-specific mortality and total life expectancy. Epidemiology 16(4):556–562CrossRefPubMed
5.
6.
Prossnitz ER, Hathaway HJ (2015) What have we learned about GPER function in physiology and disease from knockout mice? J Steroid Biochem Mol Biol 153:114–126CrossRefPubMedPubMedCentral
7.
Yamaga R, Ikeda K, Horie-Inoue K, Ouchi Y, Suzuki Y, Inoue S (2013) RNA sequencing of MCF-7 breast cancer cells identifies novel estrogen-responsive genes with functional estrogen receptor-binding sites in the vicinity of their transcription start sites. Horm Cancer 4(4):222–232CrossRefPubMed
8.
Bourdeau V, Deschênes J, Métivier R, Nagai Y, Nguyen D, Bretschneider N, Gannon F, White JH, Mader S (2004) Genome-wide identification of high-affinity estrogen response elements in human and mouse. Mol Endocrinol 18(6):1411–1427CrossRefPubMed
9.
Kamalakaran S1, Radhakrishnan SK, Beck WT (2005) Identification of estrogen-responsive genes using a genome-wide analysis of promoter elements for transcription factor binding sites. J Biol Chem 280(22):21491–21497CrossRefPubMed
10.
Sotoca AM, Vervoort J, Rietjens I MCM, Gustafsson JA. (2012) Human ERα and ERβ Splice Variants: Understanding Their Domain Structure in Relation to Their Biological Roles in Breast Cancer Cell Proliferation. Biochemistry, Prof. Deniz Ekinci (Ed.), ISBN: 978-953-51-0076-8, InTech.
11.
Xu Z, Liu J, Gu L, Ma X, Huang B, Pan X (2016) Research progress on the reproductive and non-reproductive endocrine tumors by estrogen-related receptors. J Steroid Biochem Mol Biol 158:22–30CrossRefPubMed
12.
Li M, Chai HF, Peng F, Meng YT, Zhang LZ, Zhang L, Zou H, Liang QL, Li MM, Mao KG, Sun DX, Tong MY, Deng ZQ, Hou ZJ, Zhao Y, Li J, Wang XC, Lv SS, Zhang QQ, Yu X, Lam EW, Liu Q, Cui XN, Xu J (2018) Estrogen receptor β upregulated by lncRNA-H19 to promote cancer stem-like properties in papillary thyroid carcinoma. Cell Death Dis 9(11):1120CrossRefPubMedPubMedCentral
13.
Rubio GA, Catanuto P, Glassberg MK, Lew JI, Elliot SJ (2018) Estrogen receptor subtype expression and regulation is altered in papillary thyroid cancer after menopause. Surgery 163(1):143–149CrossRefPubMed
14.
Zhang Y, Wei F, Zhang J, Hao L, Jiang J, Dang L, Mei D, Fan S, Yu Y, Jiang L (2017) Bisphenol A and estrogen induce proliferation of human thyroid tumor cells via an estrogen-receptor-dependent pathway. Arch Biochem Biophys 633:29–39CrossRefPubMed
15.
16.
Pierdominici M, Maselli A, Locatelli SL, Ciarlo L, Careddu G, Patrizio M, Ascione B, Tinari A, Carlo-Stella C, Malorni W, Matarrese P, Ortona E (2017) Estrogen receptor β ligation inhibits Hodgkin lymphoma growth by inducing autophagy. Oncotarget 8(5):8522–8535CrossRefPubMed
17.
Maia DM1, Sciarrotta J, Abendroth K, Blatt J (2000) Sex steroid receptors in Hodgkin's disease. Leuk Lymphoma 39(3-4):365–371CrossRefPubMed
18.
Teske E1, Besselink CM, Blankenstein MA, Rutteman GR, Misdorp W (1987) The occurrence of estrogen and progestin receptors and anti-estrogen binding sites (AEBS) in canine non-Hodgkin's lymphomas. Anticancer Res 7(4B):857–860PubMed
19.
Ladikou EE, Kassi E (2017) The emerging role of estrogen in B cell malignancies. Leuk Lymphoma 58(3):528–539CrossRefPubMed
20.
Yakimchuk K, Jondal M, Okret S (2013) Estrogen receptor α and β in the normal immune system and in lymphoid malignancies. Mol Cell Endocrinol 375(1-2):121–129CrossRefPubMed
21.
Mukhopadhyay M, Das C, Kumari M, Sen A, Mukhopadhyay B, Mukhopadhyay B (2017) Spectrum of meningioma with special reference to prognostic utility of ER,PR and Ki67 expression. J Lab Physicians 9(4):308–313CrossRefPubMedPubMedCentral
22.
Hsu DW, Efird JT, Hedley-Whyte ET (1997) Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg 86(1):113–120CrossRefPubMed
23.
Kuroi Y, Matsumoto K, Shibuya M, Kasuya H (2018) Progesterone Receptor Is Responsible for Benign Biology of Skull Base Meningioma. World Neurosurg 118:e918–e924CrossRefPubMed
24.
Wolfsberger S, Doostkam S, Boecher-Schwarz HG, Roessler K, van Trotsenburg M, Hainfellner JA, Knosp E (2004) Progesterone-receptor index in meningiomas: correlation with clinico-pathological parameters and review of the literature. Neurosurg Rev 27(4):238–245CrossRefPubMed
25.
Liu M, Zhang K, Zhao Y, Guo Q, Guo D, Zhang J (2015) Evidence for involvement of steroid receptors and coactivators in neuroepithelial and meningothelial tumors. Tumour Biol 36(5):3251–3261CrossRefPubMed
26.
Jaffrain-Rea ML, Petrangeli E, Ortolani F, Fraioli B, Lise A, Esposito V, Spagnoli LG, Tamburrano G, Frati L, Gulino A (1996) Cellular receptors for sex steroids in human pituitary adenomas. J Endocrinol 151(2):175–184CrossRefPubMed
27.
Caronti B, Palladini G, Bevilacqua MG, Petrangeli E, Fraioli B, Cantore G, Tamburrano G, Carapella CM, Jaffrain-Rea ML (1993) Effects of 17 beta-estradiol, progesterone and tamoxifen on in vitro proliferation of human pituitary adenomas: correlation with specific cellular receptors. Tumour Biol 14(1):59–68CrossRefPubMed
28.
Natale CA, Li J, Zhang J, Dahal A, Dentchev T, Stanger BZ, Ridky TW. (2018) Activation of G protein-coupled estrogen receptor signaling inhibits melanoma and improves response to immune checkpoint blockade. Elife. 7. pii: e31770.
29.
Tian W, Pang W, Ge Y, He X, Wang D, Li X, Hou H, Zhou D, Feng S, Chen Z, Yang Y (2018) Hepatocyte-generated 27-hydroxycholesterol promotes the growth of melanoma by activation of estrogen receptor alpha. J Cell Biochem 119(3):2929–2938CrossRefPubMed
30.
Dika E, Fanti PA, Vaccari S, Capizzi E, Degiovanni A, Gobbi A, Piraccini BM, Ribero S, Baraldi C, Ravaioli GM, Fiorentino M, Patrizi A (2017) Oestrogen and progesterone receptors in melanoma and nevi: an immunohistochemical study. Eur J Dermatol 27(3):254–259CrossRefPubMed
31.
Bredow L, Stützel L, Böhringer D, Gundlach E, Reinhard T, Auw-Haedrich C (2014) Progesterone and estrogen receptors in conjunctival melanoma and nevi. Graefes Arch Clin Exp Ophthalmol 252(2):359–365CrossRefPubMed
32.
Hiramitsu S, Ishikawa T, Lee WR, Khan T, Crumbley C, Khwaja N, Zamanian F, Asghari A, Sen M, Zhang Y, Hawse JR, Minna JD, Umetani M (2018) Estrogen Receptor Beta-Mediated Modulation of Lung Cancer Cell Proliferation by 27-Hydroxycholesterol. Front Endocrinol (Lausanne) 9:470CrossRef
33.
Ding X, Li L, Tang C, Meng C, Xu W, Wei X, Guo Z, Zhang T, Fu Y, Zhang L, Wang X, Lin L, Liang J (2018) Cytoplasmic expression of estrogen receptor β may predict poor outcome of EGFR-TKI therapy in metastatic lung adenocarcinoma. Oncol Lett 16(2):2382–2390PubMedPubMedCentral
34.
Stevanato Filho PR, Aguiar Júnior S, Begnami MD, Ferreira FO, Nakagawa WT, Spencer RMSB, Bezerra TS, Boggiss PE, Lopes A (2018) Estrogen Receptor β as a Prognostic Marker of Tumor Progression in Colorectal Cancer with Familial Adenomatous Polyposis and Sporadic Polyps. Pathol Oncol Res 24(3):533–540CrossRefPubMed
35.
Liu D (2016) Gene signatures of estrogen and progesterone receptor pathways predict the prognosis of colorectal cancer. FEBS J 283(16):3115–3133CrossRefPubMed
36.
Kuo CT, Lee WS (2016) Progesterone receptor activation is required for folic acid-induced anti-proliferation in colorectal cancer cell lines. Cancer Lett 378(2):104–110CrossRefPubMed
37.
Ge H, Yan Y, Tian F, Wu D, Huang Y (2018) Prognostic value of estrogen receptor α and estrogen receptor β in gastric cancer based on a meta-analysis and The Cancer Genome Atlas (TCGA) datasets. Int J Surg 53:24–31CrossRefPubMed
38.
Iyer JK, Kalra M, Kaul A, Payton ME, Kaul R (2017) Estrogen receptor expression in chronic hepatitis C and hepatocellular carcinoma pathogenesis. World J Gastroenterol 23(37):6802–6816CrossRefPubMedPubMedCentral
39.
Tsai HW, Ho CL, Cheng SW, Lin YJ, Chen CC, Cheng PN, Yen CJ, Chang TT, Chiang PM, Chan SH, Ho CH, Chen SH, Wang YW, Chow NH, Lin JC. (2018) Progesterone receptor membrane component 1 as a potential prognostic biomarker for hepatocellular carcinoma. World J Gastroenterol 2018 Mar 14;24(10):1152-1166.
40.
Garg D, Man Ng SS, Baig KM, Driggers P, Segars J (2017) Progesterone-Mediated Non-Classical Signaling. Trends Endocrinol Metab 28(9):656–668CrossRefPubMed
41.
Wetendorf M, DeMayo FJ (2014) Progesterone receptor signaling in the initiation of pregnancy and preservation of a healthy uterus. Int J Dev Biol 58(2-4):95–106CrossRefPubMedPubMedCentral
42.
Mani SK, Oyola MG (2012) Progesterone signaling mechanisms in brain and behavior. Front Endocrinol (Lausanne) 3:7CrossRef
43.
44.
Murthy V, Chamberlain RS (2012) Menopausal symptoms in young survivors of breast cancer: a growing problem without an ideal solution. Cancer Control 19(4):317–329CrossRefPubMed
45.
Cobleigh MA, Berris RF, Bush T (1994) Estrogen replacement therapy in breast cancer survivors. A time for change. JAMA 272(7):540–545CrossRefPubMed
46.
Vassilopoulou-Sellin R, Asmar L, Hortobagyi GN, Klein MJ, McNeese M, Singletary SE, Theriault RL (1999) Estrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively. J Clin Oncol 17(5):1482–1487CrossRefPubMed
47.
Vassilopoulou-Sellin R, Theriault R, Klein MJ (1997) Estrogen Replacement Therapy in Women with Prior Diagnosis and Treatment for Breast Cancer. Gynecol Oncol 65(1):89–93CrossRefPubMed
48.
O'Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS (2001) Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 93(10):754–762CrossRefPubMed
49.
Holmberg L, Anderson H, HABITS steering and data monitoring committees (2004) HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped. Lancet 363(9407):453–455CrossRef
50.
Lupo M, Dains JE, Madsen LT (2015) Hormone Replacement Therapy: An Increased Risk of Recurrence and Mortality for Breast Cancer Patients? J Adv Pract Oncol 6(4):322–330PubMedPubMedCentral
51.
Brewster A, Do KA, Thompson PA, Hahn KA, Sahin AA, Cao Y, Stewart MM, Murray JL, Hortobagyi GN, Bondy ML (2007) Relationship between epidemiologic risk factors and breast cancer recurrence. J Clin Oncol 25(28):4438–4444CrossRefPubMed
52.
Holmberg L, Iversen OE, Rudenstam CM, Hammar M, Kumpulainen E, Jaskiewicz J, Jassem J, Dobaczewska D, Fjosne HE, Peralta O, Arriagada R, Holmqvist M, Maenpaa J, HABITS Study Group (2008) Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 100(7):475–482CrossRefPubMed
53.
Fahlén M, Fornander T, Johansson H, Johansson U, Rutqvist LE, Wilking N, von Schoultz E (2013) Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer 49(1):52–59CrossRefPubMed
54.
Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, Mol-Arts M, Kloosterboer L, Mosca L, Christiansen C, Bilezikian J, Kerzberg EM, Johnson S, Zanchetta J, Grobbee DE, Seifert W, Eastell R, Trial Investigators LIFT (2008) The Effects of Tibolone in Older Postmenopausal Women. N Engl J Med 359(7):697–708CrossRefPubMedPubMedCentral
55.
Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, Vassilopoulou-Sellin R, Yip CH, Egberts J, Mol-Arts M, Mulder R, van Os S, Beckmann MW, LIBERATE Study Group (2009) Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 10(2):135–146CrossRefPubMed
56.
Bundred NJ, Kenemans P, Yip CH, Beckmann MW, Foidart JM, Sismondi P, Schoultz B, Vassilopoulou-Sellin R, Galta RE, Lieshout EV, Mol-Arts M, Planellas J, Kubista E (2012) Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy. Breast Cancer Res 14(1):R13CrossRefPubMedPubMedCentral
57.
Sismondi P1, Kimmig R, Kubista E, Biglia N, Egberts J, Mulder R, Planellas J, Moggio G, Mol-Arts M, Kenemans P (2011) Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients--data from LIBERATE trial. Maturitas 70(4):365–372CrossRefPubMed
58.
Pruthi S1, Simon JA, Early AP (2011) Current overview of the management of urogenital atrophy in women with breast cancer. Breast J 17(4):403–408CrossRefPubMed
59.
Durna EM1, Wren BG, Heller GZ, Leader LR, Sjoblom P, Eden JA (2002) Hormone replacement therapy after a diagnosis of breast cancer: Cancer recurrence and mortality. Med J Aust 177(7):347–351CrossRefPubMed
60.
Fahlen M, Fornander T, Johansson H, Johansson U, Rutqvist LE, Wilking M, von Schoultz E (2013) Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer 49:52–59CrossRefPubMed
61.
Decker DA, Pettinga JE, VanderVelde N, Huang RR, Kestin L, Burdakin JH (2003) Estrogen replacement therapy in breast cancer survivors: A matched-controlled series. Menopause 10(4):277–285CrossRefPubMed
62.
DiSaia PJ, Brewster WR, Ziogas A, Anton-Culver H (2000) Breast cancer survival and hormone replacement therapy: A cohort analysis. Am J Clin Oncol 23(6):541–545CrossRefPubMed
63.
Finch A, Evans G, Narod SA (2012) BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations. Women's Health (Lond) 8(5):543–555CrossRef
64.
Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P, Armel S, Lynch HT, Senter L, Eisen A, Singer CF, Foulkes WD, Jacobson MR, Sun P, Lubinski J, Narod SA, Hereditary Breast Cancer Clinical Study Group (2018) Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers. JAMA Oncol 4(8):1059–1065CrossRefPubMedPubMedCentral
65.
Guidozzi F1, Daponte A (1999) Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial. Cancer 86(6):1013–1018CrossRefPubMed
66.
Mascarenhas C1, Lambe M, Bellocco R, Bergfeldt K, Riman T, Persson I, Weiderpass E (2006) Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. Int J Cancer 119(12):2907–2915CrossRefPubMed
67.
Eeles RA, Morden JP, Gore M, Mansi J, Glees J, Wenczl M, Williams C, Kitchener H, Osborne R, Guthrie D, Harper P, Bliss JM. (2015) Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT randomized trial. J Clin Oncol 2015 Dec 10;33(35):4138-4144.
68.
Pergialiotis V, Pitsouni E, Prodromidou A, Frountzas M, Perrea DN, Vlachos GD (2016) Hormone therapy for ovarian cancer survivors: systematic review and meta-analysis. Menopause 23(3):335–342CrossRefPubMed
69.
Eeles RA, Tan S, Wiltshaw E, Fryatt I, A’Hern RP, Shepherd JH, Harmer CL, Blake RP, Chilvers CE (1991) Hormone replacement therapy and survival after surgery for ovarian. BMJ 302(6771):259–262CrossRefPubMedPubMedCentral
70.
Ursic-Vrscaj M, Bebar S, Zakelj MP (2001) Hormone replacement therapy after invasive ovarian serous cystadeno carcinoma treatment: the effect on survival. Menopause 8(1):70–75CrossRefPubMed
71.
Bešević J, Gunter MJ, Fortner RT, Tsilidis KS, Weiderpass E, Onland-Moret NE, Dossus L, Tjønneland A, Hansen L, Overvad K, Mesrine S, Baglietto L, Clavel-Chapelon F, Kaaks R, Aleksandrova K, Boeing H, Trichopoulou A, Lagiou P, Bamia C, Masala G, Agnoli C, Tumino R, Ricceri F, Panico S, HB (as) Bueno-de-Mesquita, Peeters PH, Jareid M, Quirós JR, Duell EJ, Sánchez MJ, Larrañaga N, Chirlaque MD, Barricarte A, Dias JA, Sonestedt E, Idahl A, Lundin E, Wareham NJ, Khaw KT, Travis RC, Rinaldi S, Romieu I, Riboli E, Merritt MA. (2015) Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study. Br J Cancer 113(11):1622-1631.
72.
Pergialiotis V, Pitsouni E, Prodromidou A, Frountzas M, Perrea DN, Vlachos GD (2016) Hormone therapy for ovarian cancer survivors: systematic reviewand meta-analysis. Menopause 23(3):335–342CrossRefPubMed
73.
Kuhle CL, Kapoor E, Sood R, Thielen JM, Jatoi A, Faubion SS (2016) Menopausal hormone therapy in cancer survivors: A narrative review of the literature. Maturitas 92:86–96CrossRefPubMed
74.
Biglia N, Bounous VE, Sgro LG, D'Alonzo M, Gallo M (2015) Treatment of climacteric symptoms in survivors of gynaecological cancer. Maturitas 82(3):296–298CrossRefPubMed
75.
Del Carmen MG, Rice LW (2017) Management of menopausal symptoms in women with gynecologic cancers. Gynecol Oncol 146(2):427–435CrossRefPubMed
76.
Singh P, Oehler MK. (2010) Hormone replacement after gynaecological cancer. Maturitas 2010 Mar;65(3):190-197.
77.
Creasman WT, Henderson D, Hinshaw W, Clarke-Pearson DL (1986) Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 67(3):326–330PubMed
78.
Lee RB, Burke TW, Park RC (1990) Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 36(2):189–191CrossRefPubMed
79.
Chapman JA, DiSaia PJ, Osann K, Roth PD, Gillotte DL, Berman ML (1996) Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 175(5):1195–1200CrossRefPubMed
80.
Suriano KA, McHale M, McLaren CE, Li KT, Re A, DiSaia PJ (2001) Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet Gynecol 97(4):555–560PubMed
81.
Ayhan A, Taskiran C, Simsek S, Sever A (2006) Does immediate hormone replacement therapy affect the oncologic outcome in endometrial cancer survivors? Int J Gynecol Cancer 16(2):805–808CrossRefPubMed
82.
Barakat RR, Bundy BN, Spirtos NM, Bell J, Mannel RS, Gynecologic Oncology Group Study (2006) Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology group study. J Clin Oncol 24(4):587–592CrossRefPubMed
83.
Shim SH, Lee SJ, Kim SN (2014) Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis. Eur J Cancer 50(9):1628–1637CrossRefPubMed
84.
Pink D, Lindner T, Mrozek A, Kretzschmar A, Thuss-Patience PC, Dörken B, Reichardt P (2006) Harm or benefit of hormone replacement in metastatic low-grade endometrial stromal sarcoma: single centre experience with 10 cases and review of literature. Gynecol Oncol 101(3):464–469CrossRefPubMed
85.
Kelley TW, Borden EC, Goldblum JR (2004) Estrogen and progesterone receptor expression in uterine and extrauterine leiomyosarcomas: an immunohistochemical study. Appl Immunohistochem Mol Morphol 12(4):338–341CrossRefPubMed
86.
Kapp DS, Shin JY, Chan JK (2008) Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer 112(4):820–830CrossRefPubMed
87.
88.
Ploch E. (1987) Hormonal replacement therapy in patients after cervical cancer treatment. Gynecol Oncol 1987 Feb;26(2):169-177.
89.
Madsen BS1, Jensen HL, van den Brule AJ, Wohlfahrt J, Frisch M (2008) Risk factors for invasive squamous cell carcinoma of the vulva and vagina--population-based case-control study in Denmark. Int J Cancer 122(12):2827–2834CrossRefPubMed
90.
Sherman KJ, Daling JR, McKnight B, Chu J (1994) Hormonal factors in vulvar cancer. A case–control study. J Reprod Med 39(11):857–861PubMed
91.
Somoye GO, Gull S (2005) Adenocarcinoma of the vaginal vault following prolonged unopposed estrogen hormone replacement therapy. J Obstet Gynaecol 25(2):220–221CrossRefPubMed
92.
Kincade PW, Medina KL, Payne KJ, Rossi MI, Tudor KS, Yamashita Y, Kouro T (2000) Early B-lymphocyte precursors and their regulation by sex steroids. Immunol Rev 175:128–137CrossRefPubMed
93.
Kauss MA, Reiterer G, Bunaciu RP, Yen A (2008) Human myeloblastic leukemiacells (HL-60) express a membrane receptor for estrogen that signals and modulates retinoic acid-induced cell differentiation. Exp Cell Res 314(16):2999–3006CrossRefPubMedPubMedCentral
94.
Li Q, Kopecky KJ, Mohan A, Willman CL, Appelbaum FR, Weick JK, Issa JP (1999) Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia. Clin Cancer Res 5(5):1077–1084PubMed
95.
Tavani A, Pregnolato A, La Vecchia C, Franceschi S (1997) A case-control study of reproductive factors and risk of lymphomas and myelomas. Leuk Res 21(9):885–888CrossRefPubMed
96.
Nelson RA, Levine AM, Bernstein L (2001) Reproductive factors and risk of intermediate-or high-grade B-cell non-Hodgkin’s lymphoma in women. J Clin Oncol 19(5):1381–1387CrossRefPubMed
97.
Medina KL, Strasser A, Kincade PW (2000) Estrogen influences the differentiation, proliferation, and survival of early B-lineage precursors. Blood 95(6):2059–2067CrossRefPubMed
98.
Preti HA, Cabanillas F, Talpaz M, Tucker SL, Seymour JF, Kurzrock R (1997) Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med 127(3):186–194CrossRefPubMed
99.
Cheleuitte D, Mizuno S, Glowacki J (1998) In vitro secretion of cytokines by human bone marrow: effects of age and estrogen status. J Clin Endocrinol Metab 83(6):2043–2051PubMed
100.
Yang X, Wang C, He X, Wei J, Wang Y, Li X, Xu LP (2017) Hormone therapy for premature ovarian insufficiency patients with malignant hematologic diseases. Climacteric 20(3):268–273CrossRefPubMed
101.
Tauchmanovà L, Selleri C, De Rosa G, Sammartino A, Di Carlo C, Musella T, Martorelli C, Lombardi G, Rotoli B, Nappi C, Colao A (2007) Estrogen-progestin therapy in women after stem cell transplant: our experience and literature review. Menopause 14(2):320–330CrossRefPubMed
102.
Black PM (1997) Hormones, radiosurgery and virtual reality: new aspects of meningioma management. Can J Neurol Sci 24(4):302–306CrossRefPubMed
103.
Carroll RS, Brown M, Zhang J, DiRenzo J, Font De Mora J, McL. Black P. (2000) Expression of a subset of steroid receptor cofactors is associated with progesterone receptor expression in meningiomas. Clin Cancer Res 6:3570–3575.
104.
Hsu DW, Efird JT, Hedley-Whyte ET (1997) Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg 86(1):113–120CrossRefPubMed
105.
Hilbig A, Barbosa-Coutinho LM (1998) Meningiomas and hormonal receptors. Immunohistochemical study in typical and non-typical tumors. Arq Neuropsiquiatr 56(2):193–199CrossRefPubMed
106.
107.
O'Shea T, Crowley RK, Farrell M, MacNally S, Govender P, Feeney J, Gibney J, Sherlock M. (2016) Growth of a progesterone receptor-positive meningioma in a female patient with congenital adrenal hyperplasia. Endocrinol Diabetes Metab Case Rep. 2016 pii: 16-0054.
108.
Benson VS, Kirichek O, Beral V, Green J (2015) Menopausal hormone therapy and central nervous system tumor risk: large UK prospective study and meta-analysis. Int J Cancer 136(10):2369–2377CrossRefPubMed
109.
Qi ZY, Shao C, Huang YL, Hui GZ, Zhou YX, Wang Z (2013) Reproductive and exogenous hormone factors in relation to risk of meningioma in women: a meta-analysis. PLoS One 8(12):e83261CrossRefPubMedPubMedCentral
110.
Harland TA, Freeman JL, Davern M, McCracken DJ, Celano EC, Lillehei K, Olson JJ, Ormond DR (2018) Progesterone-only contraception is associated with a shorter progression-free survival in premenopausal women with WHO Grade I meningioma. J Neuro-Oncol 136(2):327–333CrossRef
111.
Christin-Maître S, Delemer B, Touraine P, Young J (2007) Prolactinoma and estrogens: pregnancy, contraception and hormonal replacement therapy. Ann Endocrinol (Paris) 68(2-3):106–112CrossRef
112.
Sathyapalan T, González S, Atkin SL (2009) Effect of long-term, high-dose estrogen treatment on prolactin levels: a retrospective analysis. Climacteric 12(5):427–430CrossRefPubMed
113.
De Giorgi V, Gori A, Savarese I, D’Errico A, Scarfì F, Papi F, Maio V, Covarelli P, Massi D, Gandini S (2017) Role of BMI and hormone therapy in melanoma risk: a case–control study. J Cancer Res Clin Oncol 143(7):1191–1197CrossRefPubMed
114.
115.
Botteri E, Støer NC, Sakshaug S, Graff-Iversen S, Vangen S, Hofvind S, Ursin G, Weiderpass E (2017) Menopausal hormone therapy and risk of melanoma: Do estrogens and progestins have a different role? Int J Cancer 141(9):1763–1770CrossRefPubMed
116.
Marzagalli M, Marelli MM, Casati L, Fontana F, Moretti RM, Limonta P (2016) Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility. Front Endocrinol (Lausanne) 7:140CrossRef
117.
Marzagalli M, Casati L, Moretti RM, Montagnani Marelli M, Limonta P (2015) Estrogen receptor beta agonists differentially affect the growth of human melanoma cell lines. PLoS One 10(7):e0134396CrossRefPubMedPubMedCentral
118.
Thomas C, Gustafsson JA (2011) The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 11(8):597–608CrossRefPubMed
119.
de Giorgi V, Gori A, Grazzini M, Rossari S, Scarfì F, Corciova S, Verdelli A, Lotti T, Massi D (2011) Estrogens, estrogen receptors and melanoma. Expert Rev Anticancer Ther 11(5):739–747CrossRefPubMed
120.
de Giorgi V, Gori A, Gandini S, Papi F, Grazzini M, Rossari S, Simoni A, Maio V, Massi D (2013) Oestrogen receptor beta and melanoma: a comparative study. Br J Dermatol 168(3):513–519CrossRefPubMed
121.
122.
123.
Miki Y, Abe K, Suzuki S, Suzuki T, Sasano H (2011) Suppression of estrogen actions in human lung cancer. Mol Cell Endocrinol 340(2):168–174CrossRefPubMed
124.
Chlebowski RT, Anderson GL, Manson JE, Schwartz AG, Wakelee H, Gass M, Rodabough RJ, Johnson KC, Wactawski-Wende J, Kotchen JM, Ockene JK, O'Sullivan MJ, Hubbell FA, Chien JW, Chen C, Stefanick ML. (2010) Lung cancer among postmenopausal women treated with estrogen alone inthe women’s health initiative randomized trial. J Natl Cancer Inst 2010 Sep 22;102(18):1413-1421.
125.
Clague J, Reynolds P, Henderson KD, Sullivan-Halley J, Ma H, Lacey JV Jr, Chang S, Delclos GL, Du XL, Forman MR, Bernstein L (2014) Menopausal hormone therapy and lung cancer-specific mortality following diagnosis:the California teachers study. PLoS One 9(7):e103735CrossRefPubMedPubMedCentral
126.
Ganti AK1, Sahmoun AE, Panwalkar AW, Tendulkar KK, Potti A (2016) Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol 24(1):59–63CrossRef
127.
Miki Y, Abe K, Suzuki S, Suzuki T, Sasano H (2011) Suppression of estrogen actions in human lung cancer. Mol Cell Endocrinol 340(2):168–174CrossRefPubMed
128.
Regula J, Rupinski M, Kraszewska E, Polkowski M, Pachlewski J, Orlowska J, Nowacki MP, Butruk E (2006) Colonoscopy in colorectal-cancerscreening for detection of advanced neoplasia. N Engl J Med 355(18):1863–1872CrossRefPubMed
129.
Koo JH, Jalaludin B, Wong SK, Kneebone A, Connor SJ et al (2008) Improved survival in young women with colorectal cancer. Am J Gastroenterol 103(6):1488–1495CrossRefPubMed
130.
McArdle CS, McMillan DC, Hole DJ (2003) Male gender adversely affects survival following surgery for colorectal cancer. Br J Surg 90(6):711–715CrossRefPubMed
131.
Murphy N, Strickler HD, Stanczyk FZ, Xue X, Wassertheil-Smoller S, Rohan TE, Ho GY, Anderson GL, Potter JD, Gunter MJ. (2015) A prospective evaluation of endogenous sex hormone levels and colorectal cancer risk in postmenopausal women. J Natl Cancer Inst.107(10). pii: djv210.
132.
Limsui D, Vierkant RA, Tillmans LS, Wang AH, Weisenberger DJ, Laird PW, Lynch CF, Anderson KE, French AJ, Haile RW, Harnack LJ, Potter JD, Slager SL, Smyrk TC, Thibodeau SN, Cerhan JR, Limburg PJ (2012) Postmenopausal hormone therapy and colorectal cancer risk by molecularly defined subtypes among older women. Gut 61(9):1299–1305CrossRefPubMed
133.
Newcomb PA, Zheng Y, Chia VM, Morimoto LM, Doria-Rose VP, Templeton A, Thibodeau SN, Potter JD (2007) Estrogen plus progestin use,microsatellite instability, and the risk of colorectal cancer in women. Cancer Res 67(15):7534–7539CrossRefPubMed
134.
Grodstein F, Newcomb PA, Stampfer MJ (1999) Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 106(5):574–582CrossRefPubMed
135.
Nanda K, Bastian LA, Hasselblad V, Simel DL (1999) Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol 93(5 Pt 2):880–888PubMed
136.
Lin KJ, Cheung WY, Lai JY, Giovannucci EL (2012) The effect of estrogen vs.combined estrogen-progestogen therapy on the risk of colorectal cancer. Int J Cancer 130(2):419–430CrossRefPubMed
137.
Caiazza F1, Ryan EJ1, Doherty G1, Winter DC2, Sheahan K3 (2015) Estrogen receptors and their implications in colorectal carcinogenesis. Front Oncol 5:19CrossRefPubMedPubMedCentral
138.
Stevanato Filho PR, Aguiar S Jr, Begnami MD, Kuasne H, Spencer RM, Nakagawa WT, Bezerra TS, Kupper BC, Takahashi RM, Filho MR, Rogatto SR, Lopes A (2017) Oestrogen receptor beta isoform expression in sporadic colorectal cancer, familial adenomatous polyposis and progressive stages of colorectal cancer. BMC Cancer 17:754CrossRefPubMedPubMedCentral
139.
Stevanato Filho PR, Aguiar Júnior S, Begnami MD, Ferreira FO, Nakagawa WT, Spencer RMSB, Bezerra TS, Boggiss PE, Lopes A. (2018) Estrogen Receptor β as a Prognostic Marker of Tumor Progression in Colorectal Cancer with Familial Adenomatous Polyposis and Sporadic Polyps. Pathol Oncol Res (3):533-540.
140.
Topi G, Ehrnström R, Jirström K, Palmquist I, Lydrup ML, Sjölander A (2017) Association of the oestrogen receptor beta with hormone status and prognosis in a cohort of female patients with colorectal cancer. Eur J Cancer 83:279–289CrossRefPubMed
141.
Karami S, Daugherty SE, Schonfeld SJ, Park Y, Hollenbeck AR, Grubb RL 3rd, Hofmann JN, Chow WH, Purdue MP (2013) Reproductive factors and kidney cancer risk in 2 US cohort studies, 1993-2010. Am J Epidemiol 177(12):1368–1377CrossRefPubMedPubMedCentral
142.
Zucchetto A, Talamini R, Dal Maso L, Negri E, Polesel J, Ramazzotti V, Montella M, Canzonieri V, Serraino D, La Vecchia C, Franceschi S (2008) Reproductive, menstrual, and other hormone-related factors and risk of renal cell cancer. Int J Cancer 123(9):2213–2216CrossRefPubMed
143.
144.
Molokwu JC, Prizment AE, Folsom AR (2007) Reproductive characteristics and risk of kidney cancer: IowaWomen’s. Maturitas 58(2):156–163CrossRefPubMed
145.
McCredie M, Stewart JH (1992) Risk factors for kidney cancer in New South Wales, Australia. II. Urologic disease, hypertension, obesity, and hormonal factors. Cancer Causes Control 3(4):323–331CrossRefPubMed
146.
Zhao XH, Gu SZ, Liu SX, Pan BR (2003) Expression of estrogen receptor and estrogen receptor messenger RNA in gastric carcinoma tissues. World J Gastroenterol 9(4):665–669CrossRefPubMedPubMedCentral
147.
Matsui M, Kojima O, Kawakami S, Uehara Y, Takahashi T (1992) The prognosis of patients with gastric cancer possessing sex hormone receptors. Surg Today 22(5):421–425CrossRefPubMed
148.
Ur Rahman MS, Cao J (2016) Estrogen receptors in gastric cancer: Advances and perspectives. World J Gastroenterol 22(8):2475–2482CrossRefPubMed
149.
Tang W, Liu R, Yan Y, Pan X, Wang M, Han X, Ren H, Zhang Z (2017) Expression of estrogen receptors and androgen receptor and their clinical significance in gastric cancer. Oncotarget 8(25):40765–40777CrossRefPubMedPubMedCentral
150.
Kim HW, Kim JH, Lim BJ, Kim H, Kim H, Park JJ, Youn YH, Park H, Noh SH, Kim JW, Choi SH (2016) Sex Disparity in Gastric Cancer: Female Sex is a Poor Prognostic Factor for Advanced Gastric Cancer. Ann Surg Oncol 23(13):4344–4351CrossRefPubMed
151.
Brusselaers N, Maret-Ouda J, Konings P, El-Serag HB, Lagergren J (2017) Menopausal hormone therapy and the risk of esophageal and gastric cancer. Int J Cancer 140(7):1693–1699CrossRefPubMed
152.
Adami HO1, Persson I, Hoover R, Schairer C, Bergkvist L (1989) Risk of cancer in women receiving hormone replacement therapy. Int J Cancer 44(5):833–839CrossRefPubMed
153.
154.
Montella M, D’Arena G, Crispo A, Capunzo M, Nocerino F, Grimaldi M, Barbieri A, D’Ursi AM, Tecce MF, Amore A, Galdiero M, Ciliberto G, Giudice A (2015) Role of Sex Hormones in the Development and Progression of Hepatitis B Virus-Associated Hepatocellular Carcinoma. Int J Endocrinol 2015:854530CrossRefPubMedPubMedCentral
155.
Hassan MM, Botrus G, Abdel-Wahab R, Wolff RA, Li D, Tweardy D, Phan AT, Hawk E, Javle M, Lee JS, Torres HA, Rashid A, Lenzi R, Hassabo HM, Abaza Y, Shalaby AS, Lacin S, Morris J, Patt YZ, Amos CI, Khaderi SA, Goss JA, Jalal PK, Kaseb AO (2017) Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 15(11):1791–1799CrossRefPubMedPubMedCentral
156.
Basakci A, Kirkali Z, Tuzel E, Yorukoglu K, Mungan MU, Sade M (2002) Prognostic significance of estrogen receptor expression in superficial transitional cell carcinoma of the urinary bladder. Eur Urol 41(3):342–345CrossRefPubMed
157.
Fernandez E, Gallus S, Bosetti C, Franceschi S, Negri E, La Vecchia C (2003) Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies. Int J Cancer 105(3):408–412CrossRefPubMed
158.
Godoy G, Gakis G, Smith CL, Fahmy O (2016) Effects of Androgen and Estrogen Receptor Signaling Pathways on Bladder Cancer Initiation and Progression. Bladder Cancer 2(2):127–137CrossRefPubMedPubMedCentral
159.
Dellagrammaticas D, Bryden AA, Collins GN (2001) Regression of metastatic transitional cell carcinoma in response to tamoxifen. J Urol 165(5):1631CrossRefPubMed
160.
Hsu CH, Chen J, Wu CY, Cheng AL, Pu YS (2001) Combination chemotherapy of cisplatin, methotrexate, vinblastine, , and high-dose tamoxifen for transitional cell carcinoma. Anticancer Res 21(1B):711–715PubMed
161.
Shang Z, Li Y, Hsu I, Zhang M, Tian J, Wen S, Han R, Messing EM, Chang C, Niu Y, Yeh S (2016) Targeting estrogen/estrogen receptor alpha enhances Bacillus Calmette-Guérin efficacy in bladder cancer. Oncotarget 7(19):27325–27335CrossRefPubMedPubMedCentral
162.
Moleti M, Sturniolo G, Di Mauro M, Russo M, Vermiglio F (2017) Female Reproductive Factors and Differentiated Thyroid Cancer. Front Endocrinol (Lausanne) 8:111CrossRef
163.
Galanti MR, Hansson L, Lund E, Bergström R, Grimelius L, Stalsberg H, Carlsen E, Baron JA, Persson I, Ekbom A (1996) Reproductive history and cigarette smoking as risk factors for thyroid cancer in women: a population-based case-control study. Cancer Epidemiol Biomark Prev 5(6):425–431
164.
Mack WJ, Preston-Martin S, Bernstein L, Qian D, Xiang M. (1999) Reproductive and hormonal risk factors for thyroid cancer in Los Angeles county females. Cancer Epidemiol Biomarkers Prev. 8(11):991-997.
165.
Rossing MA, Voigt LF, Wicklund KG, Daling JR (2000) Reproductive factors and risk of papillary thyroid cancer in women. Am J Epidemiol 151(8):765–772CrossRefPubMed
166.
Sakoda LC, Horn-Ross PL (2002) Reproductive and menstrual history and papillary thyroid cancer risk: the San Francisco bay area thyroid cancer study. Cancer Epidemiol Biomark Prev 11(1):51–57
167.
Memon A, Darif M, Al-Saleh K, Suresh A (2002) Epidemiology of reproductive and hormonal factors in thyroid cancer: evidence from a case-control study in the Middle East. Int J Cancer 97(1):82–89CrossRefPubMed
168.
Truong T, Orsi L, Dubourdieu D, Rougier Y, Hémon D, Guénel P (2005) Role of goiter and of menstrual and reproductive factors in thyroid cancer: a population- based case-control study in New Caledonia (South Pacific), a very high incidence area. Am J Epidemiol 161(11):1056–1065CrossRefPubMed
169.
Sturniolo G, Zafon C, Moleti M, Castellví J, Vermiglio F, Mesac J (2016) Immunohistochemical Expression of Estrogen Receptor-α and Progesterone Receptor in Patients with Papillary Thyroid Cancer. Eur Thyroid J 5(4):224–230CrossRefPubMedPubMedCentral
170.
Yi JW, Kim SJ, Kim JK, Seong CY, Yu HW, Chai YJ, Choi JY, Lee KE (2017) Upregulation of the ESR1 Gene and ESR Ratio (ESR1/ESR2) is Associated with a Worse Prognosis in Papillary Thyroid Carcinoma: The Impact of the Estrogen Receptor α/β Expression on Clinical Outcomes in Papillary Thyroid Carcinoma Patients. Ann Surg Oncol 24(12):3754–3762CrossRefPubMed
171.
Jastrzebska H, Gietka-Czernel M, Zgliczyński S (2001) Hormonal replacement therapy in women after surgery for thyroid cancer treated with suppressive doses of L-thyroxine. Wiad Lek 54(Suppl 1):383–388PubMed
172.
Tang B, Lv J, Li Y, Yuan S, Wang Z, He S (2015) Relationship between female hormonal and menstrual factors and pancreatic cancer: a meta-analysis of observational studies. Medicine (Baltimore) 94(7):e177CrossRef
173.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288(3):321–333CrossRefPubMed
174.
van der Schouw YT, van der Graaf Y, Steyerberg EW, Eijkemans JC, Banga JD (1996) Age at menopause as a risk factor for cardiovascular mortality. Lancet 347(9003):714–718CrossRefPubMed
175.
de Villiers TJ, Gass ML, Haines CJ, Hall JE, Lobo RA, Pierroz DD, Rees M (2013) Global Consensus Statement on Menopausal Hormone Therapy. Climacteric 16(2):203–204CrossRefPubMed
Metadata
Title
Hormone Replacement Therapy in Cancer Survivors – Review of the Literature
Authors
Tamás Deli
Mónika Orosz
Attila Jakab
Publication date
01-01-2020
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 1/2020
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-018-00569-x

Other articles of this Issue 1/2020

Pathology & Oncology Research 1/2020 Go to the issue

Original Article

Association Between the Interleukin-17 Gene Polymorphism -197G>A and the Risk of Prostate Cancer in a Galician Population

Original Article

Genetic Polymorphisms in miR-146a, miR-196a2 and miR-125a Genes and its Association in Prostate Cancer

Original Article

Comparison of Native Aspirates and Cytological Smears Obtained by EUS-Guided Biopsies for Effective DNA/RNA Marker Testing in Pancreatic Cancer

Original Article

Gene Expression Profiles in Chemokine (C-C Motif) Ligand 21-Overexpressing Pancreatic Cancer Cells

Short Communication

Spectrum of Pathogenic Germline Mutations in Chinese Lung Cancer Patients through Next-Generation Sequencing

Original Article

Immunomodulatory Effect of Lentinan on Aberrant T Subsets and Cytokines Profile in Non-small Cell Lung Cancer Patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits